It has become apparent that traditional, target-based methods for drug discovery are not as effective for antimicrobials and neglected diseases. However, drug discovery efforts using the combined forces of academic and industrial expertise in an atmosphere of open innovation have shown promise.The Structural Genomics Consortium and the Tuberculosis Structural Genomics Consortium have successfully formed open collaborations with many academic and industrial partners.  Our expertise encompasses not only the atomic structure of key drug targets, but also high throughput protein expression, characterization, and enzymatic screening � all key elements for early stage drug discovery. This high throughput streaming is a perfect fit for neglected disease drug discovery, which needs accelerated efforts to develop novel therapeutics quickly.We discuss our successes with drug discovery and research, and present the tools and resources available within structural genomics that will more efficiently impact collaborative drug discovery for neglected diseases in the future.

Collaborative drug discovery and structural genomics: Positive impact for neglected disease research

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.